Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377)

Journal of Infectious Diseases

Volumn 183, Issue 12, 2001, Pages 1732-1738

  Eshleman, Susan H ^a   Krogstad, Paul ^b   Jackson, J Brooks ^a   Wang, You Gan ^c   Lee, Sophia ^c   Wei, Lee Jen ^c   Cunningham, Shawn ^a   Wantman, Michael ^c   Wiznia, Andrew ^d   Johnson, George ^f   Nachman, Sharon ^e   Palumbo, Paul ^g  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e STONY BROOK UNIVERSITY   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g MOUNT SINAI HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ANTIVIRAL ACTIVITY; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MUTATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TREATMENT PLANNING; VIROLOGY;

ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG RESISTANCE, MICROBIAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; LAMIVUDINE; MALE; MUTATION; NELFINAVIR; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, VIRAL; STAVUDINE; TREATMENT FAILURE; VIRAL LOAD;

EID: 0035877141     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/320728     Document Type: Article

References (26)

1. Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management
2. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an international AIDS society-USA panel
3. Drug-resistance genotyping in HIV-I therapy: The VIRADAPT randomised controlled trial
4. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. Viradapt study: Week 48 follow-up
5. A randomized study of anti-retroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS
6. High-level resistance to zidovudine but not to zalcitabine or didanosine in human immunodeficiency virus from children receiving antiretroviral therapy
7. Zidovudine therapy and HIV type 1 mutations in children with symptomatic HIV type 1 infection: Effect of switching to didanosine or zidovudine plus didanosine therapy. Italian Multicenter Study Group on HIV Mutations in Children
8. HIV-1 reverse transcriptase codon 215 mutation and clinical outcome in children treated with zidovudine
9. Effects of zidovudine use during pregnancy on resistance and vertical transmission of human immunodeficiency virus type 1
10. Selective vertical transmission of HIV-1 antiretroviral resistance mutations
11. Identification of the K103N mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission
12. Transmission from one child to another of human immunodeficiency virus type 1 with a zidovudine-resistance mutation
13. Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: Week 24 results of a randomized controlled trial: PACTG 377
14. Combining dependent tests with incompletely repeated measurements
15. A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V
16. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro
17. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: Virus fitness in the absence and in the presence of drug
18. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1
19. Development and significance of the HIV-1 reverse transcriptase M184V mutation during combination therapy with lamivudine, zidovudine, and protease inhibitors
20. Effectiveness of 3TC in HIV clinical trials may be due in part to the MI84V substitution in 3TC-resistant HIV-1 reverse transcriptase
21. Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: The relative roles of drift and selection
22. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir
23. Correlation between human immunodeficiency virus genotypic resistance and virologic response in patients receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine
24. Treatment of human immuno-deficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate
25. Predictors of response to treatment of HIV-1 infected infants and children with the protease inhibitor nelfinavir mesylate